<DOC>
	<DOCNO>NCT01821118</DOCNO>
	<brief_summary>Cerebral Amyloid Angiopathy ( CAA ) condition cause build-up protein call amyloid , predominantly AÎ²40 , within wall brain blood vessel , especially blood vessel occipital lobe brain . Probable CAA may define two hemorrhage brain cortex individual 55 year age old . This study examine study drug ( PF-04360365 ) vs. placebo ( saline ) 10 mg/kg - Day 1 maintenance dose study drug ( PF-04360365 ) vs. placebo ( saline ) 7.5mg/kg Days 30 60 . Subjects follow 6 month receive last dose study medication .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability Efficacy PF-04360365 Adults With Probable Cerebral Amyloid Angiopathy</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
	<mesh_term>Cerebral Amyloid Angiopathy , Familial</mesh_term>
	<criteria>Patients diagnose probable CAA use Boston criterion ; clinical cognitive impairment In general good health Comorbid diagnosis clinically document Alzheimer 's disease significant cognitive impairment Clinically significant syncope , epilepsy , head trauma clinically significant unexplained loss consciousness within last 5 year Subject 's body weight exceed 100kg Women childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cerebral amyloid angiopathy ( CAA )</keyword>
	<keyword>cerebrovascular reactivity</keyword>
	<keyword>functional MRI</keyword>
	<keyword>randomize</keyword>
	<keyword>double blind</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>